The Native Antigen Company Expands Infectious Disease Portfolio
Antigen designed to support immunoassay and vaccine development applications
Articles by The Native Antigen Company
The Native Antigen Company Expands Range of Norovirus-Like Particles
Addition of six new reagents, including four which are unique to the market
The Native Antigen Company Launches SARS-CoV-2 Neutralization Assay Development Kit
This kit can be used to identify and qualitatively assess the ability of antibodies to neutralize SARS-CoV-2-receptor binding
The Native Antigen Company Introduces Range of Veterinary Reagents
Antigens and antibodies for livestock and companion animal diseases to support development of diagnostics and vaccines
The Native Antigen Company Launches Range of SARS-CoV-2 Specific Antibodies
These 10 antibodies recognize different epitopes of the SARS-CoV-2 Spike glycoprotein, nine of which are SARS-CoV-2-specific and do not cross-react with other human coronaviruses
Collaboration to Increase COVID-19 Antigen Production for Diagnostic Kits and Vaccine Development
OXGENE and The Native Antigen Company are developing an improved, scalable approach to SARS-CoV-2 antigen manufacture
The Native Antigen Company Introduces Novel Coronavirus Antigens
Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development
The Native Antigen Company Introduces Antigen and Antibody Conjugation Kits
Highly scalable kits enable researchers to prepare liquid-stable antigen and antibody conjugates with a wide range of labels including enzymes, fluorochromes, and biotin
The Native Antigen Company Introduces Rubella Virus-Like Particles
Recombinant expression of Rubella VLPs offers a reliable source of reagents for consistency in immunoassay development and manufacturing